News

Specialty drug coupons - a double-edged sword of improved adherence, increased costs


 

FROM HEALTH AFFAIRS

References

While the availability of coupons can help defray out-of-pocket costs and improve access and adherence to high-cost specialty drugs, it may also result in higher costs to the health system.

Patients used drug coupons to pay for $21.2 million of $35.3 million in out-of-pocket costs, according to an analysis of 265,000 prescriptions worth $911 million in 2013. The coupons generally dropped a patient’s out-of-pocket costs to less than $250 per prescription, a point below which patients were “far less likely” to abandon prescriptions in cases of specialty anti-inflammatory drugs and treatments for multiple sclerosis (Health Affairs 2014;33:1761-9 [doi:10.1377/hlthaff.2014.0497]).

But while the use of coupons demonstrated that the lower cost led to lower prescription abandonment rates, it also allowed patients to circumvent cost-containment measures that pharmacy benefit managers employ.

Coupons can help defray out-of-pocket costs and improve access to specialty drugs, but may also result in higher costs to the health system. © Photodisc / ThinkStockPhotos.com

Coupons can help defray out-of-pocket costs and improve access to specialty drugs, but may also result in higher costs to the health system.

“We found that drug coupons were extremely effective in lowering patients’ costs to less than $50 per prescription, thus eliminating the incentive to select a preferred drug,” wrote Catherine I. Starner, Pharm.D., senior health outcomes researcher at pharmacy benefit manager Prime Therapeutics, and her colleagues.

To control costs at the health system level, tighter controls could be placed on specialty drugs at the pharmacy benefit manager level, according to Dr. Starner and her colleagues. Such controls could include prior authorization or the use of step therapies,as well as excluding coverage of nonpreferred drugs. The latter strategy, however, could make drug access a problem, especially if physicians are not aware of an insurance plan taking these steps.

Excluding specialty drugs “makes the patient responsible for the entire cost of the drug,” the authors noted. “If prescribers are unaware of such exclusions, or if patients require specific therapies, such exclusions may impose considerable costs on patients” and potentially lead to access issues.

gtwachtman@frontlinemedcom.com

Recommended Reading

Slowed Infusions Cut Hypersensitivity Reactions in Rituximab Desensitization
MDedge Hematology and Oncology
MS Use Leads to Free Campath for Leukemia Patients
MDedge Hematology and Oncology
Will They Still Give Strong to Lance Armstrong's Cancer Charity?
MDedge Hematology and Oncology
Bill seeks to keep biologic copays down
MDedge Hematology and Oncology
All glucocorticoids linked to increased risk of VTE
MDedge Hematology and Oncology
Evidence of delayed cancer detection in MS patients
MDedge Hematology and Oncology
iPad app could change how MS is measured, treated
MDedge Hematology and Oncology